zum Inhalt springen


The clinical testing of new interventions for the prevention and treatment of infectious diseases, especially during outbreaks, requires a specialized clinical study network. This has been particularly evident during the COVID-19 pandemic. In addition to the immunological and infectious disease expertise needed within the clinical network, low-threshold accessible platforms for the exchange of data and protocols from controlled studies and individual treatment approaches are necessary. With this in mind, we have established the Network for Immunological-Infectious Clinical Studies (NIKS) and will continue to develop it as a platform of the NUM in close cooperation with the therapeutic intervention platform (NAPKON-TIP).